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ANTI-IDIOTYPE MONOCLONAL ANTIBODY

ential reactivity to melanomas, ncuroblastomas and adeno
carcinomas. They are anti-ganglioside antibodies with

1A7 AND USE FOR THE TREATMENT OF
MELANOMA AND SMALL CELL

speci?c isotopes such as IgG3 and lgG2a.

CARCINOMA

U.S. Pat. No. 5,242,824 to Hellstrom et al. discloses novel
monoclonal antibodies reactive with a glycolipid cell mem

TECHNICAL FIELD

brane antigen on the surface of human carcinomas. Mono
clonal antibodies react with carcinomas of the lung, ovary
and colon. They show no detectable reactivity with mela

The present invention relates isolation of anti-idiotypic
antibody 1A7 raised against anti-GDZmAb 1462a and its

noma cells.

use for the treatment and detection of melanoma and small

U.S. Pat. No. 5,270,202 to Rayehaudhuri discloses a

cell carcinoma.

novel anti-idiotypic antibody lMelpg2 which is speci?c for
BACKGROUND

melanoma cells. It can be used for the diagnosis and
treatment of melanoma tumors.

Monoclonal antibody to the human ganglioside GD2

U.S. Pat. No. 5,208,146 to lrie discloses murine mono
clonal anti-idiotypc antibodies raised against human mono
clonal anti-ganglioside antibody known as L612. The mono

antigen, and to other melanoma and small cell lung carci
nomas are known. For example, U.S. Pat. No. 4,675,287 to
Reisfeld et al. discloses a monoclonal antibody to the human

clonal antibody is speci?c for melanoma cells.

ganglioside GD2 antigen. This antibody is reactive with

U.S. Pat. No. 4,904,596 to Hakomori discloses a hybri

melanoma and oat cell lung carcinoma cells. This mono

antibody by immunoactive mechanisms. lntemational

doma cell line and monoclonal antibody to fucoganglioside,
6B, which is present in human colonic adenocarcinoma and
lung carcinoma cells.

Patent Publication WO 8600909 to Reisfeld, R. A. ct al is
directed to a “Monoclonal antibody directed to human

clonal antibodies recognized by gpl30 antigen of human

clonal antibody is tolerated by the human immune system
and thus human immune system does not remove this

ganglioside GDZ.” This patent is the international patent

U.S. Pat. No. 5,009,995 to Albino et al. discloses mono
25

al. described above. More speci?cally, the publication dis
closes a non-human, mammalian monoclonal receptor pro
duced by a hybridoma formed by fusion of cells from a

U.S. Pat. No. 4,918,164 to Hellstrom et al. discloses

anti-idiotypic antibodies for immunization against tumor,
for inhibition of immune suppression mediated by suppres

myeloma cell line and lymphocytes that produce antibodies
that react with ganglioside GD2 from a mammal immunized

with a ganglioside GDz-containing immunogen is disclosed.
U.S. Pat. No. 4,693,966 to Houghton et al. discloses
human monoclonal antibodies from lymphocytes of patients
with malignant melanoma. The monoclonal antibodies of
Houghton et al. speci?cally bind to antigens found on
surfaces of renal, lung and breast cancer cells. The antibody
also detects the cytoplasmic antigen expressed by cells of

sor T cells or suppressor factors expressing an anti-idiotype

against tumors bearing the oncofetal antigen. Monoclonal
antibody recognizes a human melanoma associated GD3

ganglioside antigen.
35

Journal of Immunology, Volume 150, 142A, 1993 dis
closes an abstract of Chatterjee et al. entitled “Syngeneic
Monoclonal Anti-IdiotypeAntibodies Against a Monoclonal
Antibody to Human Melanoma-Associated Antigen.” The
abstract generally discloses that the 1A7 antibody was
isolated, but does not disclose a method of obtaining it or
provide any of its particular properties or uses.
Patent No. EP 280209 is directed to “Monoclonal anti

neuroectodermal origin, such as melanoma cells.
U.S. Pat. No. 4,965,498 to Yamasaki et al. discloses a

monoclonal antibody speci?c to a sugar chain containing an
N-glycolylneuramine acid and has the ability to bind to at

least N-glycolyl GM2 ganglioside. Page 1, lines 55—56
acknowledges that monoclonal antibodies against human
melanoma which react with glycolipids such as GD2 gan
glioside are known.

cells. The monoclonal antibodies are useful in the detection

of the gpl30 antigen and human cells, including melanoma
cells, which contain the antigen.

publication related to U.S. Pat. No. 4,675,287 to Reisfeld et

bodies against melanoma-associated antigens, hybridoma
45

cell lines producing these antibodies, and uses of the mono
clonal antibodies”. This patent to Thurin et al. discloses

hybridomas producing antibodies against ganglioside anti

U.S. Pat. No. 5,305,559 to Nicolson et al. is directed to

gens GD2 and GD3 which are non-reactive with other

ganglioside antigens.

methods and compositions for the identi?cation of meta
static human tumors. Monoclonal antibodies of this patent

None of the patents nor literature recognize an anti- _
react with human tumor cells and are prepared against a 580 50 idiotypic monoclonal antibody speci?c for melanoma and

kilodalton glycoprotein antigen gp580. Antibodies are spe

small cell carcinoma cells which is not tolerated by the
ci?c for lung metastasis from breast tissue and are not
human immune system.
reactive with melanoma tumors.
Neuroblastomas are highly malignant tumors occurring
U.S. Pat. No. 5,091,177 to Hellstrom et al. issued is 55 during infancy and early childhood. Except for Wilms’
directed to monoclonal antibodies which de?ne a glycolipid
tumor, they are the most common retroperitoneal tumors in
antigen associated with human non-small cell lung carcino
children. Neuroblastomas arise most commonly in the adre
mas. Activity with melanoma cells is not disclosed. The
nal medulla, but they may also develop in other sympathetic
monoclonal antibody has an IgG2 isotope.
ganglia within the thorax or abdomen. These tumors metas
U.S. Pat. No. 5,134,075 to Hellstrom et al. discloses a 60 tasize early with wide spread involvement of lymph nodes,

monoclonal antibody which binds strongly to a protein

liver, bone, lung and marrow. The prognosis is often good
when the tumor is diagnosed prior to obvious metastasis, but
with metastasis, prognosis is poor despite the extensive use

antigen associated with human tumors, including lung
tumors as well as melanomas and sarcomas. The monoclonal

antibody is of the subclass IgG2a.
U.S. Pat. No. 5,240,833 to Nudelman et al. discloses
monoclonal antibodies that bind to tumor-associated gan

gliosides. The monoclonal antibodies have selected prefer

of radical surgery, deep X-ray therapy, and chemotherapeu
65

tie agents.

Several antigenic determinants have recently been
detected on neuroblastoma cells with monoclonal antibodies

5,612,030
3
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(Mabs). See Seeger, Ann. Intern. Med, 97, 873 (1982);

determinant on fetal tissues, especially fetal brain, as well as
on adult brain and other neural tissues. In addition, cross

Wikstrand et al., Cancer Res., 42, 267(1982); Wikstrand et
al., J. Neuroimmunlogy, 3, 43 (1982); Eisenbarth et al., Proc.
Nat’l Acad. Sci. (USA), 76, 4913 (1979); Liao et al., Eur. J.

reactions of such antibodies have also been reported with

normal kidney, fibroblasts, rnyoblasts, and thymocytes, See

Immunol, 11, 450 (1981); Seeger et al., Cancer Res., 4,

ger et al., Cancer Res., supra, and Seeger et al., J. Immunol,
supra, with islet cells, Eisenbarth et al., Proc. Nat’l Acad.
Sci. (USA), supra, and with spleen cells, Wikstrand et al.,
Cancer Res., supra.
Furthermore, some of the monoclonal antibodies reported

2714 (1981); Kennett et al., Advances in Neuroblastoma

Research, p. 209, Raven Press, New York (Evans ed.)
(1980); Seeger et al., J. Immunol., 128, 983 (1982); Kems
head et al., Pediatr. Res., 15, 1282 (1981).
A panel of such antibodies has been reported to be helpful
in the differential diagnosis of neuroblastoma and lympho
blastic disorders, Kemshead et al., Pediatr. Res., supra;

in the literature are not only restricted in their reactivity to
neuroectoderrnal tumors, such as neuroblastoma, melanoma
and glioma, but also show binding to some forms of leuke

Kemshead et al., Lancet, I2 (1983). In these same studies,
antibodies were used either in immunoperoxidase assays

mia, osteogenic sarcoma, rhabdomyosarcoma, leiomyosar
coma and even to carcinomas of the lung and breast, Seeger,
Ann. Intern. Med, supra.

with tumor tissue sections or in direct immuno?uorescence
assays to detect tumor cells in bone marrow aspirates.
The effective use of Mabs directed to any tumor-associ—

ated antigens as diagnostic reagents depends on the quantity,
expression and chemical nature of the corresponding anti
gen. In this regard, Mabs directed to tumor-associated gan

A monospeci?c human monoclonal antibody, (anti-OFA
I-2), produced in vitro by a lymphoblast cell line that
20

gliosides have been useful in de?ning antigens associated
with melanoma, neuroblastoma, colon carcinoma, and
adenocarcinoma, Hakomori et al., J. Natl. Cancer Inst.,
71,231 (1983). One of these antibodies was reported to
detect a ganglioside antigen shed into the serum of patients

25

with colon carcinomas, Koprowski et al., Science, 212, 53
(1981). Some of the above neuroblastoma—associated anti

79, 5666 (1982). However, problems have arisen when such
a human monoclonal antibody is used for immunoperoxi
dase assays of human tissues in that the anti-human second
ary antibody required for such assays causes a large amount

gens are present in fetal neural tissues whereas others are

expressed by both fetal and adult neural tissues. Seeger, Ann.
Intern. Med., supra.

originated from a melanoma patient was reported to detect
a GD2 ganglioside on human melanoma, glioma and neu
roblastoma cells, while reportedly not reacting with a variety
of cell lines derived from carcinomas and from diiferent
lymphoid tumors, Cahan et al., Proc. Nat’l Acad. Sci.
(USA), supra, and Irie et al., Proc. Nat’l Acad. Sci. (USA),

of non-speci?c background reactivity.
30

Most of the monoclonal antibodies utilized to detect the
neuroblastoma-associated antigens are not restricted in their

reactivity to neuroectoderrnal tumors like melanoma and
glioma but also recognize common antigens on other malig
nancies such as a variety of sarcomas and leukemias, Seeger, 35

Ann. Intern. Med., supra. In addition, only some of the
antigenic structures on neuroblastoma cells recognized by
monoclonal antibodies have been partially characterized by

Heterogeneity of neuroblastomas with regard to cell sur

face antigenic expression has been reported in Seeger, Ann.
Intern. Med, supra; Kemshead et al., Pediatr. Res., supra;
Kemshead et al., Int. J. Cancer, 27, 447(1981); and, Kems
head et al., Proc. Am. Assoc. Cancer Res., 2, 399 (1981). As
discussed in these publications, Mab A2 B5 failed to react
with some human neuroblastoma lines tested, and quantita
tive differences in antigenic expression were observed
between di?‘erent cell cultures. Analysis of tumor cells in

heavily in?ltrated bone marrow aspirates indicated that only

immunochemical means. Thus, a monoclonal antibody des
70 percent of the samples reacted with A2 B5, suggesting
ignated Mab 390 was reported to react with an antigenic 40 that the heterogeneity seen in the expression of antigen on
determinant of human Thy-l that had a molecular weight of
cell lines is paralleled in fresh tumor material, Kemshead et

25,000 daltons. Seeger et al., J. Immunol., supra.
Another Mab, designated A2 B5, was reported to recog

al., Int. J. Cancer, supra.

nize a GD2 ganglioside on neurons, Eisenbarth et al., Proc.

detecting and treating melanoma and small cell carcinoma.

Thus there is a need in the art for new methods of

Nat’l Acad. Sci. (USA), supra. A human monoclonal anti
The present invention overcomes the de?ciencies of the
body produced in vitro by a lymphoblast cell line from a
prior art by providing an anti-idiotypic antibody 1A7 raised
melanoma patient was also reported to react with a GD2
against anti-GD2mAb l4G2a, which is not tolerated by the
ganglioside present on neuroectoderm-derived tumors,
human immune system, and thus may be used as a vaccine
Cahan et al., Proc. Nat’l Acad. Sci. (USA), 79, 7629 (1982). 50 to stimulate the immune system. This property of the present
From a biological point of view, gangliosides are of
monoclonal antibody makes it ideal for a new immuno
considerable interest since they have been implicated in a
therapeutic approach to cancer.

variety of cellular functions, including cell-cell adhesion and
communication, as well as cell-substrate interactions, Hako
mori et al., J. Nat’l Cancer Inst., supra. Recent studies have 55

emphasized the importance of gangliosides for tumor

growth regulation by demonstrating di?erences in ganglio
side composition among cells expressing various degrees of
tumorigenicity, Itaya et al., Proc. Nat’l Acad. Sci. (USA), 73,
1568 (1976). Consequently, the use of monoclonal antibod
ies directed to ganglioside determinants aids in further
delineating the role of gangliosides in these processes.
Most of the monoclonal antibodies directed against neu

Disclosure of the Invention
It is an object of the present invention to provide an

anti-idiotype monoclonal antibody 1A7, which is the inter
nal image of the GD2 ganglioside antigen which is highly
expressed on malignant melanoma cell and small cell car

cinoma cells.
It is another object of the invention to provide an antibody
which generates an active immunity to GD2 antigen which

is highly expressed on malignant melanoma cell and small

cell carcinoma cells.
far, Wikstrand et al., Cancer Res., supra; Wikstrand et al., J. 65
A further object of the invention is to provide a pharma
Neuro-immunology, supra; Eisenbarth et al., Proc Nat’l
ceutical composition comprising anti—idiotype monoclonal
Acad. Sci. (USA), supra, recognize a common antigenic
antibody 1A7, and a pharmaceutically acceptably carrier.

roblastoma-associated antigens that have been reported thus

5,612,030
5
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A still further object of the invention provides a method
of treatment of metastatic melanoma and small cell lung
cancer comprising administering a pharmaceutically effec
tive amount of a pharmaceutical composition of the inven
tion to a patient in need of treatment.
In a preferred embodiment the method may be adminis—
tered to a patient who has had disease removed by surgery,
radiation or chemotherapy and remains at high risk for
recurrence of metastatic melanoma and small cell lung

During the pendency of this application, access to the
deposit will (a) be forwarded to one determined by the
Commissioner to be entitled thereto;
(b) all restrictions imposed by the depositor on the avail
ability to the public of the deposited material will be

irrevocably removed upon the granting of the patent,
(c) the deposit will be maintained for a period of at least
thirty years or at least ?ve years after the most recent request

for the furnishings of a sample of the deposited material; and
(d) the deposit will be replaced should it become neces

cancer.

Another object of the invention is to provide a lA7

sary due to inviability, contamination or loss of capability to
function in the manner described in the speci?cation.

monoclonal antibody which can be used as a substitute for

GD2 antigen in all biochemical and serological assays, such
DESCRIPTION OF THE INVENTION

as a monoclonal antibody probe. The 1A7 monoclonal

antibody probe may be incorporated into a test kit in

15

Anti-idiotype monoclonal antibody 1A7, is the internal
image of a GD2 ganglioside antigen which is expressed on

accordance with the present invention, such as a diagnostic
test kit.
The above and other objects of the invention will become
readily apparent to those of skill in the relevant an from the

malignant melanoma cells and on small cell carcinoma cells.

The anti-idiotype antibody 1A7, raised against a known

anti-GD2 antibody (1462a), mimics GD2 antigen. However,

following detailed description and ?gures, wherein only the

it is not tolerated by the human immune system. This

preferred embodiments of the invention are shown and

property of the present monoclonal anti-idiotype antibody

described, simply by way of illustration of the best mode of
carrying out the invention. As is readily recognized the
invention is capable of modi?cations within the skill of the
relevant art without departing from the spirit and scope of

makes it ideal for a new immuno-therapeutic approach to
cancer.

25

the invention.

Discussion below represents the results of immunization
and treatment of monkeys with anti-Id 1A7 (isotype IgGl-k)
which mimics GD2. Murine monoclonal anti—Id 1A7 was

raised against anti-GD2 mAb l4G2a (isotype IgG2a—k)
obtained from Scripps Research Institute, La lolla. In pre
vious studies of the inventors, small animals, such as mice
and rabbits, were immunized three to four times bi-weekly
with anti-Id 1A7 coupled to KLH and mixed with Freund’s

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows the binding of puri?ed Ab3 to Ab2 1A7 on

the plate by sandwich radioimmunoassay.
FIG. 2 demonstrates the inhibition of Abl-Ab2 binding

Adjuvant. The production of anti-GD2 antibodies were

by monkey Ab3 or vice-versa (Ab2—Ab3 binding inhibition)

induced in the animals.

which shows that Abl and Ab2 share idiotopes and Ab3 is 35
A murine monoclonal antibody mAB (IgGZak) which
true anti-anti-idiotypic in nature.
binds to the ganglioside GD2 in human melanoma, neuro
FIG. 3 shows the inhibition of binding of 1251 labelled
blastoma, glioma and sarcoma has been used to generate
l4G2a antibody to GD2 positive melanoma cell line M2l/P6
monoclonal antibodies (Ab2) in BALB/c mice. The culture
in presence of different concentrations of Abl and Ab3.
supernatants from primary fusion cells were initially
screened by a sandwich radioimmunoassay using Id as
Parallel inhibition curves were obtained using either puri?ed
Abl or Ab3 form monkey sera. This suggests that Abland
antigen.
Ab3 bind to the same epitope on GD2.
Several Ab2 hybridomas were obtained that reacted with
FIG. 3A shows the inhibition of binding of I25 I-labelled
the immunizing Id of l4G2a (Abl) and did not react with

14G2a antibody to puri?ed GD2 on the plate by Abl and
Ab3.
FIG. 4 shows the binding of Abl and Ab3 to different
gangliosides on the plate by ELISA assay. 250 ng of GD2
and other gangliosides were coated per well of 96-well
microtiter plates, blocked and incubated with different con
centrations of puri?ed Abl and Ab3. The bound antibody

45

any isotype or allotype matched control immunoglobulins.
Three of the mAb2s reacted with the antigen binding site

(paratope), since they inhibited the binding between 1251
labelled 14G2a and the target melanoma cell line M21/P6.
One of these clones lAI-lA7 is used to raise anti-anti

idiotype antibodies (Ab3) in rabbits. Polyclonal rabbit A3
sera competed with Abl for binding to M2l/P6 cell lines

was detected using anti-Human-Ig-alkaline phosphatase

available from Scripps Institute, La Jolla, Calif, and inhib

labelled reagent and substrate. The CD. value obtained after
2 hr. using 1.5 micrograms of different antibodies per well
were plotted. At this concentration, there was only reactivity
with GD2.
FIG. 5 shows the ELISA results con?rmed by dot blot

ited the binding of radiolabelled Abl to Ab2.
The anti-idiotype monoclonal antibody to the anti-GD2
55

antibody (designated 1462a) is designated 1A7. This anti
Idiotype antibody is, therefore, the internal image of the
GD2 ganglioside antigen which is highly expressed on
malignant melanoma cell and small cell carcinoma cells.

analysis.

The anti-idiotype antibody mimics the GD2 ganglioside
antigen. The present inventors have determined in mice,

STATEMENT OF DEPOSIT

A deposit of the hybridoma producing the 1A7 mono
clonal antibody was made prior to the ?ling date of the
above-identi?ed patent application under the terms of the
Budapest Treaty with the American Type Culture Collection,
Parklawn Drive, Rockville, Md., USA, Accession No.
HB-ll786.

rabbits and monkeys, all acceptable experimental animal
models, that when the anti-idiotype antibody is injected

65

intraeutaneously into these animals that they develop an
anti-anti-idiotype antibody that is like anti-GD2 and mimics
the original anti-GD2 (l4G2a).
A pair of male and female cynomolgus monkeys were
immunized with 2 mg of 1A7 (intact IgGl) mixed with 100

5,612,030
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pg QS-2l (Cambridge Biotech), 3 to 4 times. Sera obtained
from monkeys 2 weeks after 3rd and 4th immunizations

Radioimmuno assay (RIA)
Additional characterization of Ab2 was done by RIA. For

were analyzed.

the direct binding assay between Abl and Ab2, puri?ed Abl
was used to coat plate (500 ng/well) and the binding of

Anti-anti-Id(Ab3) antibody from monkey sera was puri
?ed ?rst by adsorption and then elution from a?inity column
lA7-sepharose 4B and then by passing through a negative

radiolabeled Ab2 to Abl was tested in the presence of
different Abl, Ab2 or several control mouse myeloma pro

a?inity column of mouse IgG-sepharose 4B. The flow
through material has been used as “puri?ed” Ab3 and

terns.

compared with the reactivity of Abl (l4G2a) in different

Anti-Idiotype assay

assays. 2.6 mg of puri?ed Ab3 was recovered from 10 ml of
sera (i.e. about 260 micrograms Ab3 per ml of serum) from

To determine whether Ab2 recognizes the paratope of
Abl, the following inhibition assays were done. Target

monkey #PRO 685 and #PRO 778.
This anti-idiotype antibody can be used to treat patients
with malignant melanoma and small cell lung cancer to
generate an active immunity to the GD2 antigen which is

96-well tissue culture plates. The binding of radiolabeled

highly expressed on their tumor cells. These patients are not

Abl to cultured cells was tested for inhibition in the presence

capable in vivo of generating the active immunity to GD2,
but by using the anti-idiotype as a surrogate antigen, they are

preparation.

tumor cells (M2l/P6) which contain GD2 antigen as a cell
surface constituent, were grown as con?uent monolayer in

of different Ab2 culture supernatant and also puri?ed Ab2

able to overcome tolerance to this antigen and generate an

active immunity to GD2 antigen.
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These new anti-idiotype antibodies represent a new

Inhibition assay

Percent inhibition of the assay was calculated according

immunotherapeutic approach to cancer. The antibodies may
be used for the treatment and therapy of metastatic mela

to the formula:

noma and small cell lung cancer. The antibodies may also be
25
used as a prevention for recurrent disease in patients who
have had disease removed by surgery, radiation or chemo

therapy and who remain at high risk for recurrence.
30

%1nhrb1tion —l [—————RmaX_RC ] X 100
in which R, is the average cpm of the experimental well with
inhibitors, RC is the average background cpm and RMAX is
the average maximum binding without any inhibitors.

Production of Ab2 (1A7)
Puri?cation of Ab2

The murine mAb l4G2a is an anti-GD2 antibody that

mediates antibody-dependent cytotoxicity and complement
mediated lysis of neuroblastoma and melanoma cell lines in
vitro. Murine monoclonal antibody l4G2a (Abl) was used
to immunize syngeneic BALB/c mice for the production of

35

To get enough puri?ed Ab2, ascites of Ab2 (1A7) hybri
domas was prepared by injecting individual pristane primed
BALB/c mice intraperitoneally with 2><l06 to lXlO7 viable
hybrid cells. The IgGl fraction was isolated from ascites by

anti-idiotype antibody (Ab2). Six to eight weeks old female

chromatography on a Protein A-Sepharose CL 4B column.

BALB/c mice were immunized four times over a period of

The purity of the isolated IgGl was checked by SDS-PAGE.

two months. The ?rst injection was given i.p. and other
injections i.p. and s.c., respectively. Mice were bled from
time to time and sera were checked for anti-idiotype activity
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by radioimmuno assay using 14G2a and MClO (iso-allotype
match control antibody) as plate coats. Three days before the
fusion, mice were boosted intravenously with l4G2a in
PBS.

Immunization of mice
45

Fusion

Fusion was done essentially following the method of Oi
and Herzenberg, by using HAT sensitive mouse myeloma
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Eight weeks old BALB/c mice (5 in each group) were
immunized with 100 pg of 1A7 coupled with KLH using
glutaraldehyde to increase the immunogenicity in the syn—
geneic mice. A total of 100 pg of Ab2 ~KLI-I were injected
i.p. with Freund’s complete adjuvant. Two weeks later the
mice were injected i.p. and s.c. with the same antigen dose

mixed with incomplete Freund’s adjuvant. After 2 weeks
rest, animals were boosted similarly at biweekly intervals.

cell line P3-653 as a fusion partner and 50% PEG. The

hybrids were selected by using HAT media. After screening
for positive wells, the cells were cloned twice by limited
dilution.

Induction of anti-anti-idiotype antibodies (Ab3) by
anti-Idiotype monoclonal antibody 1A7:

For semm antibody measurement, mice were bled every

8—lO days after the last injection. The sera were assayed for
55

anti-1A7 activity by sandwich radioimmuno assay, using
500 ng of 1A7 per well as plate coat and anti-GD2 activity

by ELISA and FACS analysis.

Selection of anti-Idiotype antibody (Ab2)
Initial screening of the hybridoma was done by sandwich
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RIA using 14G2a and MClO at a concentration of 500 ng per
well as plate coats. After overnight incubation at 4° C., the

plates were non—speci?cally blocked with 1% BSA in PBS

for 1.5 hrs. Thereafter, 100 pl of undiluted hybridoma
culture supernatant were incubated for 2 hrs. at room temp. 65

After washing with PBS, the plates were incubated with
125I-labeled 14G2a for 1.5 hrs. at room temp. with shaking.

Immunization of rabbits
Adult New Zealand white rabbits were injected s.c. with

500 ug of puri?ed Ab2-coupled to KLH, mixed with com
plete Freund’s adjuvant at day 0. Rabbits were boosted at
biweekly intervals with 500 pg of KLH coupled Ab2 mixed
with incomplete Freund’s adjuvant. Rabbits were bled 7
days after the last injection and the sera were checked for
anti-Ab2 activity as well as anti GD2 activity.

5,612,030
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Immunization of monkeys

for 2 hrs. at room temp. The strips were washed and

developed with NET and BCIP reagents (Bio Rad).

Cynomolgus monkeys (two per group, 2-4 kg weight)
received four intramascular injections of puri?ed Ab2 (2

Binding of Ab3 to M2l/P6 cells was also independently

analyzed by flow cytometry. Target cells M2l/P6 or control

mg) mixed with 100 pg of QS 21 as adjuvant. Control
monkeys were immunized with unrelated Ab2, 11Dl0
mixed with Q8 21 in the similar way. All injections were
given at 2-week intervals. Monkeys were bled 10 days after
each immunization.

cells MOLT-4 (5X105 in PBS supplemented with 0.2% BSA)
were incubated with different dilutions of Ab3 and Abl for

2 hrs. with gentle shaking at 4° C. After washing with PBS,
the staining was done with FITC labeled second antibody
and analyzed on a FACScan flow cytometer.

Puri?cation of Ab3
DETAILED DESCRIPTION OF THE FIGURES

Ab3 from immunized monkey sera was puri?ed using
lA7-Sepharose 4B as chromatography column. Bound pro
tein to the column was eluted by glycine-HCl, pH 2.7 and

coated in 96-well plate. After blocking, 50 pl of different

dialyzed against PBS. The dialyzed protein was then passed

concentration of PRO #685 or PRO #778 (Ab3) was added

through a mouse lg coupled to Sepharose 48 column until
it was completely depleted of anti-isotypic and anti-allotypic
antibodies to murine lg.

90000 cpm of radiolabeled 1A7 was added to each well and
incubated 1.5 h at room temp. The plate was washed and

Characterization of Ab3 Sandwich Assay

bound radioactivity was measured.
FIG. 2 shows an inhibition assay: 500 ng of 1A7 (Ab2) or

FIG. 1 shows a Sandwich assay: 250 ng of 1A7 (Ab2) was

and incubated 2 h at room temp with shaking. After washing,

l4G2a (Abl) was coated in 96-well plate. After blocking, 50
pl of different concentrations of PRO #685 (Ab3) along with
50 pl of radiolabeled l4G2a or 1A7 (90000 cpm) were added

To check whether Ab3 can bind to Ab2, sandwich assay
was done. Brie?y, 250 ng of Ab2 was coated in 96—well

plates. After non-speci?c blocking with 1% BSA in PBS, 50
pl of different concentration of puri?ed Ab3 from two

to each well. After 1.5 h incubation, plates were washed and
bound radioactivity was counted.

monkeys sera was added and incubated for 2 hrs. at room

FIG. 3 shows a cell binding inhibition assay: 2><l06

temperature. After washing 125l-labeled Ab2 was added and
incubated for 1.5 hrs. After washing, bound radioactivity

M21/P6 cells were incubated with different concentration of

was measured.
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Cell binding inhibition assay
To determine whether Ab3 competes with Abl for binding
to i) human melanoma cell line M2l/P6 or to ii) Ab2, the

PRO #685, PRO #778 Ab3 and l4G2a in presence of 90000
cpm of radiolabeled l4G2a for 2 hr with shaking. After
washing, radioactivity bound to the cell pellet was counted.
In FIG. 3A, 250 ng of GD2 was coated per well in 96 well
plate. Different concentrations of Ab3 and Abl along with
90,000 cpm of (lzsl-labeled) l4G2a were added. incubated
2 hrs at room temperature with shaking, washed and

binding of radiolabeled l4G2a to M21/P6 cells or to Ab2
35
was tested for inhibition in the presence of di?ferent dilutions
counted. Percent inhibition was calculated and plotted

of Ab3 and Abl preparations. Percent inhibition of the assays

against concentration of Abl and Ab3 used.

were calculated according to the formula described above.

FIG. 4 shows an ELISA assay: 250 ng of different

gangliosides were coated in 96-well plate. After blocking, 50
pl of different concentration of PRO #685 (Ab3) and l4G2a

ELISA

(Abl) were added and incubated 4 h at room temp. Bound

To measure anti-GD2 reactivity in the serum of immu

antibody was detected using alkaline phosphatase conju

nized mice, rabbit and monkeys, puri?ed GD2 (250 ng/well)

gated second antibody.

was adsorbed to 96-well plates. After blocking wells with

FIG. 5 shows a Dot Blot assay. 2 pg of di?ferent ganglio
buffer and added to wells and incubated overnight at room 45 sides were coated on PVDF cellulose membrane strips and
after blocking strips were incubated with either PRO #685
temp. After washing, the bound antibodies were detected
(Ab3) or PRO #778 (Ab3) or l4G2a (Abl) or an unrelated
using alkaline phosphatase labeled anti-mouse, anti-rabbit or
monkey Ab3 which was raised against an unrelated Ab2,
anti—human lg reagents as second antibodies.
1% BSA in PBS, test serum and Abl were diluted in same

In another experiment, different puri?ed gangliosides
(250 ng/well) were coated in 96-well plates. After blocking,

11Dl0 and PBS-BSA control, each antibody used as 10
pg/ml, 5 ml of total solution. The incubation was done for 4

50 pl of different dilutions of monkey Ab3 and Abl were

hrs at room temp. with shaking. After washing, the strips

added to wells and incubated for 4 hrs. at room temp. Plates
were washed and bound antibodies were detected using

body (1:1000 dil) for 2 hrs. at r.t., washed and developed.

alkaline phosphatase-conjugated anti human lg as second
antibodies.

were incubated with alkaline-phosphatase labeled 2nd anti
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Pharmaceutical Formulation

Dot Blot

Further, the 1A7 monoclonal antibody of the present
invention is useful in pharmaceutical compositions for sys

Reactivity of immunized sera and puri?ed Ab3 for anti
GD2 antibodies against various gangliosides was also mea

temic administration to humans and animals in unit dosage

sured by immunoblotting. Puri?ed gangliosides (2 pg each

non-parenteral solutions or suspensions oral solutions or
suspensions, oil in water or water in oil emulsions and the

forms, sterile parenteral solutions or suspensions, sterile

of GM3, GM2, GMl, GD3, GD2 and GTlb) were spotted on
strips of PVDF cellulose membrane at 1 cm intervals. After
blocking with 3% BSA in PBS, the strips were incubated
with puri?ed Ab3 or Abl (l 0 pg ml) overnight at room temp.
After washing, the strips were incubated with alkaline

phosphatase conjugated second antibody (1:1000 dilution)

like, containing suitable quantities of an active ingredient.

Formulations for parenteral and nonparenteral drug delivery
65

are known in the art as set forth in Reminglon’s Pharma

ceutical Sciences, 18th Ed, Mack Publishing (1989) incor
porated herein by reference in its entirety.
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The compounds are useful in pharmaceutical composi

We claim:

1. An antibody having all the identifying characteristics of

tions (wt %) of the active ingredient with a carrier or vehicle
in the composition in about 1 to 20% and preferably about

monoclonal antibody 1A7 produced by the hybridoma

5 to 15%.

deposited under ATCC Accession No. HB—11786.

The above 1A7 monoclonal antibody can be present alone
or in combination form with pharmaceutical carriers. The

No. HB-11786, or progeny thereof producing a monoclonal

2. Hybridoma designated 1 A7 having ATCC Accession
antibody having all the identifying characteristics of the

pharmaceutical carriers acceptable for the purpose of this

antibody produced by said hybricloma 1A7.

invention are the art known carriers that do not adversely

3. Monoclonal antibody produced by the hybridoma or

a?'ect the drug, the host, or the material comprising the drug

the progeny thereof according to claim 2.

delivery device. Suitable pharmaceutical carriers include

4. Monoclonal antibody puri?ed from the hyb?doma or

sterile water; saline, dextrose; dextrose in water or saline;
and the like.
The effective dosage for mammals may vary due to such
factors as age, weight, activity level or condition of the
subject being treated. Typically, an effective dosage of a

5. A puri?ed antibody having all the identifying charac
teristics of an antibody produced by the hybridoma accord

Biotech) in monkeys.

claim 1 in a suitable container.

the progeny thereof according to claim 2.

ing to claim 2.
6. An antibody according to claim 1 wherein said antibody
further comprises a detectable label.
compound according to the present invention is about 2mg
7. An antibody according to claim 6, wherein said detect
per injection in humans. A preferred dosage is 100 pg of
able label is selected from the group consisting of radiola
Ab2-KLH (KLH=keyhole limpet hemocyanin) when
bels, fluorescent labels and chemiluminescent labels.
injected i.p. with Freund’s complete adjuvant in small
8. A diagnostic test kit for detecting an anti-GD2 antibody
animals. A more preferred dosage range is 0.001 mg to 10 20
m a biological sample, comprising an antibody according to
mg of 1A7 (intact IgGl) mixed with QS-2l (Cambridge

9. The diagnostic kit of claim 8, wherein the antibody is

capable of binding anti-GD2.

Probe
25

11. The diagnostic kit of claim 8, wherein the detectable
label is selected from the group consisting of radiolabels,
?uorescent labels, and chemiluminescent labels.
12. The diagnostic kit of claim 8, also comprising an
anti-immunoglobulin reagent labeled with a detectable label.
13. The diagnostic kit of claim 8, wherein the biological
sample is obtained from an individual suspected of having a
GD2 antigen associated cancer.
14. The diagnostic kit of claim 8, wherein the sample is

invention may be labeled and used as a probe for the
detection of melanoma or small cell carcinoma. The probes
may be incorporated into a diagnostic test kit including a
detectable label or marker for the probe.

Diagnostic Kit
The diagnostic kit may further comprise, where necessary,
other components of the signal-producing system, including
agents for reducing background interference, control

10. The diagnostic kit of claim 8, wherein the antibody is
labeled with a detectable label.

The 1A7 anti-idiotype monoclonal antibody according to
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obtained from an individual suspected of having a cancer

selected from the group consisting of melanoma, neuroblas
toma, glioma, sarcoma, and small cell carcinoma.

reagents or an apparatus or container for conducting the test.

Examples of imaging reagents that can be used include,

15. The diagnostic kit of claim 8, wherein the biological

but are not limited to, radiolabels such as 1311, 1111n, 1231,

sample is obtained from an individual treated with an

99mTc, 32P, 1251, 31-1, and 14C, ?uorescent labels such as

antibody according to claim 1.
16. A method of preparing monoclonal antibody 1A7,
comprising purifying antibody from the hybridoma or the

?uorescein and rhodarnine, and cherniluminescers, such as
luciferin. Other labels known to those of skill in the art are

progeny thereof of claim 2.

set forth in US. Pat. No. 4,366,241 and are incorporated
herein by reference. The monoclonal antibody can be

labeled with such reagents using techniques known in the
art. For example, see Wensel and Meares, Radioimrnunoim

aging and Radioimmunotherapy, Esevier, New York (1983),
for techniques relating to the radiolabeling of proteins. (See
also, Sambrook, M. J., Fritsch, E. F. & Marriatis, T. (1989)
Molecular Cloning: A Laboratory Manual (Cold Spring
Harbor Lab., Cold Spring Harbor, N.Y., section 10, incor
porated herein by reference in its entirety).
The purpose of the above description and examples is to
illustrate some embodiments of the present invention with
out implying any limitation. It will be apparent to those of
skill in the art that various modi?cations and variations may
be made to the composition and method of the present
invention without departing from the spirit or scope of the
invention. All patents and publications cited herein are

incorporated by reference in their entireties.
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17. A method of preparing monoclonal antibody 1A7,
comprising growing the hybridoma or the progeny thereof of
claim 2.
18. A method for detecting an anti-GD2 antibody in a

biological sample, comprising the steps of providing the
diagnostic kit of claim 8, and contacting the antibody
provided in the container with any anti-GD2 antibody in the

biological sample.
19. A method for eliciting active immunity to ganglioside
GD2 in an individual, comprising administering to the
individual the antibody of claim 1.
20. The method of claim 19, wherein the active immunity

comprises production of anti-GD2 antibody by the indi
vidual.

21. The method of claim 19, further comprising mixing
the antibody with QS-21.

